Search

Displaying results 1321 - 1330 of 2421 in total
  1. Drug

    Umifenovir

    go.drugbank.com/drugs/DB13609
    Investigational

    Umifenovir is an indole-based, hydrophobic, dual-acting direct antiviral/host-targeting agent used for the treatment and prophylaxis of influenza and other respiratory infections. It has been in use in Russia for approximately 25 years a...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  2. Drug

    Metahexamide

    go.drugbank.com/drugs/DB13675
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  3. Drug

    Quingestanol

    go.drugbank.com/drugs/DB13685
    Experimental

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Prulifloxacin

    go.drugbank.com/drugs/DB11892
    Investigational

    Prulifloxacin has been investigated for the treatment of Urinary Tract Infection.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  5. Drug

    Abemaciclib

    go.drugbank.com/drugs/DB12001
    ApprovedInvestigational

    Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA gr...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, P-glycoprotein inhibitors
  6. Drug

    Voxilaprevir

    go.drugbank.com/drugs/DB12026
    ApprovedInvestigational

    Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  7. Drug

    Mafosfamide

    go.drugbank.com/drugs/DB12083
    Investigational

    Mafosfamide has been used in trials studying the treatment of Lymphoma, Leukemia, Meningeal Neoplasm, and Brain and Central Nervous System Tumors.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  8. Drug

    Tetrahydropalmatine

    go.drugbank.com/drugs/DB12093
    Investigational

    Tetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or m...

    Categories: Cytochrome P-450 CYP2C9 Substrates, Cytochrome P-450 CYP3A Inducers
  10. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. It is a lipid conjugate pro-drug of the acyclic nucleotide analogue cidofovir - this lipid conjugate improves drug delivery to the target cells a...

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 Inhibitors